Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
about
Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levelsChemotherapy-induced toxicity is highly heritable in Drosophila melanogasterContribution of tumoral and host solute carriers to clinical drug response.Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infectionEnhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.Nucleoside transporters: biological insights and therapeutic applications.Role of solute carrier transporters in pancreatic cancer: a review.Novel regulation of equlibrative nucleoside transporter 1 (ENT1) by receptor-stimulated Ca2+-dependent calmodulin binding.Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.Vertical Integration of Pharmacogenetics in Population PK/PD Modeling: A Novel Information Theoretic Method[Will molecular diagnostics become established in pancreatic pathology?].Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
P2860
Q34278045-1C6DC391-650F-4574-B4C8-7C36622EA84CQ35830711-35E924AC-65C5-491C-9FCA-8298CDA3BB55Q35946876-9CFDE2B6-DC4A-44F3-8B51-2A33F778697AQ36065593-EF76F24E-A10C-4BEA-8E1A-6D81365E1C4BQ36342657-D6FF8DB9-C83C-462E-805B-53B5DDB49B32Q37315455-9CC9251B-40AE-402A-B8FF-0B2280DD6C14Q37955222-20B397F4-946F-461A-AEB9-EBC6D9CF1908Q38031634-62D46905-6408-435F-87E0-FCEE60AA3424Q38236028-384F65C8-0929-42A7-9E84-F19708DCE1C1Q39892650-DC47D092-3C7F-4CDF-8863-0802FD396C9DQ41816813-528541F1-5E27-4A54-A83E-2D5864CB34ACQ52927417-944250EB-AF12-40BA-97BF-F02D4F6A733FQ54397309-7283B6CB-7BA8-4C05-A4BD-45828F5B64A1Q54494358-10BDC4BA-51EF-42BF-8C9F-87E0AB26CCED
P2860
Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Equilibrative nucleoside trans ...... n patients with solid tumours.
@ast
Equilibrative nucleoside trans ...... n patients with solid tumours.
@en
Equilibrative nucleoside trans ...... n patients with solid tumours.
@nl
type
label
Equilibrative nucleoside trans ...... n patients with solid tumours.
@ast
Equilibrative nucleoside trans ...... n patients with solid tumours.
@en
Equilibrative nucleoside trans ...... n patients with solid tumours.
@nl
prefLabel
Equilibrative nucleoside trans ...... n patients with solid tumours.
@ast
Equilibrative nucleoside trans ...... n patients with solid tumours.
@en
Equilibrative nucleoside trans ...... n patients with solid tumours.
@nl
P2093
P2860
P1476
Equilibrative nucleoside trans ...... n patients with solid tumours.
@en
P2093
Antonio Bononi
Carmen Barile
Caterina Bolzonella
Daniela Menon
Felice Pasini
Giorgio Crepaldi
Laura Stievano
Milena Gusella
Roberto Padrini
Silvia Meneghetti
P2860
P304
P356
10.1111/J.1365-2125.2010.03838.X
P407
P577
2011-03-01T00:00:00Z